Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Gabrielle S. Wong(Dana-Farber Cancer Institute), Jin Zhou(Dana-Farber Cancer Institute), Jie Bin Liu(Dana-Farber Cancer Institute), Zhong Wu(Dana-Farber Cancer Institute), Xinsen Xu(Dana-Farber Cancer Institute), Tianxia Li(Dana-Farber Cancer Institute), David Xu(University of Chicago Medical Center), Steven E. Schumacher(Broad Institute), Jens Puschhof(Dana-Farber Cancer Institute), James M. McFarland(Broad Institute), Charles Zou(Dana-Farber Cancer Institute), Austin Dulak(Cambridge Scientific (United States)), Les Henderson(University of Chicago Medical Center), Peng Xu(University of Chicago Medical Center), Emily O’Day(University of Chicago Medical Center), Rachel Rendak(University of Chicago Medical Center), Wei-Li Liao(OncoPlex Diagnostics (United States)), Fabiola Cecchi(OncoPlex Diagnostics (United States)), Todd Hembrough(OncoPlex Diagnostics (United States)), Sarit Schwartz(OncoPlex Diagnostics (United States)), Christopher Szeto(OncoPlex Diagnostics (United States)), Anil K. Rustgi(University of Pennsylvania), Kwok‐Kin Wong(Harvard University), J. Alan Diehl(Medical University of South Carolina), Karin Jensen(University of Illinois Urbana-Champaign), Francesco Graziano(University of Urbino), Annamaria Ruzzo(University of Urbino), Shaunt Fereshetian(Broad Institute), Philipp Mertins(Broad Institute), Steven A. Carr(Broad Institute), Rameen Beroukhim(Broad Institute), Kenichi Nakamura(Kumamoto University), Eiji Oki(Kyushu University), Masayuki Watanabe(The Cancer Institute Hospital), Hideo Baba(Kumamoto University), Yu Imamura(The Cancer Institute Hospital), Daniel V.T. Catenacci(University of Chicago Medical Center), Adam J. Bass(Broad Institute)
Cited by 273Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis